Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2025 (2025-03-31): -569.63%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-352.29%
RETURN ON EQUITY (ROE) AVG 3Y
-143.09%
RETURN ON EQUITY (ROE) AVG 5Y
-107.96%
RETURN ON EQUITY (ROE) AVG 10Y
-126.93%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$117.86M
Return on Equity (ROE)
N/A
TTM Avg
-352.29%
3Y Avg
-143.09%
5Y Avg
-107.96%
Market Cap
$116.54M
Return on Equity (ROE)
-105.40%
TTM Avg
-90.09%
3Y Avg
-60.23%
5Y Avg
-18.64%
Market Cap
$116.80M
Return on Equity (ROE)
-57.47%
TTM Avg
-26.63%
3Y Avg
16.73%
5Y Avg
210.40%
Market Cap
$114.62M
Return on Equity (ROE)
-22.45%
TTM Avg
-22.96%
3Y Avg
-17.88%
5Y Avg
-19.06%
Market Cap
$114.34M
Return on Equity (ROE)
-209.73%
TTM Avg
-196.07%
3Y Avg
-130.72%
5Y Avg
-67.26%
Market Cap
$113.70M
Return on Equity (ROE)
-478.26%
TTM Avg
-687.50%
3Y Avg
165.05%
5Y Avg
111.70%
Market Cap
$112.01M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$120.58M
Return on Equity (ROE)
-2.13%
TTM Avg
-45.09%
3Y Avg
-61.80%
5Y Avg
-44.27%
Market Cap
$111.56M
Return on Equity (ROE)
N/A
TTM Avg
129.36%
3Y Avg
-24207.46%
5Y Avg
-16163.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $117.86M | N/A | -352.29% | -143.09% | -107.96% |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | -105.40% | -90.09% | -60.23% | -18.64% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.80M | -57.47% | -26.63% | 16.73% | 210.40% |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | -22.45% | -22.96% | -17.88% | -19.06% |
| Genelux Corporation (GNLX)vs › | $114.34M | -209.73% | -196.07% | -130.72% | -67.26% |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.70M | -478.26% | -687.50% | 165.05% | 111.70% |
| Coya Therapeutics, Inc. (COYA)vs › | $112.01M | -0.05% | -43.47% | 9.13% | -18.50% |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | -2.13% | -45.09% | -61.80% | -44.27% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $111.56M | N/A | 129.36% | -24207.46% | -16163.58% |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.36M | -165.57% | -146.09% | 30.63% | 465.14% |
ROE
N/A
ROA
-167.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | -569.63% |
| 2024-09-30 | -444.28% |
| 2024-06-30 | -159.19% |
| 2024-03-31 | -236.07% |
| 2023-12-31 | -135.73% |
| 2023-09-30 | -151.13% |
| 2023-06-30 | -123.35% |
| 2023-03-31 | -157.06% |
| 2022-12-31 | -184.12% |
| 2022-09-30 | -83.02% |
| 2022-06-30 | -77.50% |
| 2022-03-31 | -123.70% |
| 2021-12-31 | -98.28% |
| 2021-09-30 | -34.75% |
| 2021-06-30 | -26.79% |
| 2021-03-31 | -24.50% |
| 2020-12-31 | -89.39% |
| 2020-09-30 | -91.16% |
| 2020-06-30 | -75.82% |
| 2020-03-31 | -71.79% |
| 2019-12-31 | -72.72% |
| 2019-09-30 | -64.67% |
| 2019-06-30 | -49.89% |
| 2019-03-31 | -41.48% |
| 2018-12-31 | -460.21% |
| 2018-09-30 | -202.23% |
| 2018-06-30 | -279.71% |
| 2018-03-31 | -204.48% |
| 2017-12-31 | -440.02% |
| 2017-09-30 | -230.08% |
| 2017-06-30 | -251.92% |
| 2017-03-31 | -147.55% |
| 2016-12-31 | -113.25% |
| 2016-09-30 | -91.51% |
| 2016-06-30 | -255.79% |
| 2016-03-31 | -149.30% |
| 2015-12-31 | -83.85% |
| 2015-09-30 | -74.96% |
| 2015-06-30 | -185.77% |
